冠心病患者ABCB1、PON1、CYP2C19基因型检测及指导PCI术后精准用药的临床意义

doi:10.3760/cma.j.issn.1007-1245.2023.07.016

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (7): 957-961.DOI: 10.3760/cma.j.issn.1007-1245.2023.07.016

冠心病患者ABCB1、PON1、CYP2C19基因型检测及指导PCI术后精准用药的临床意义

陈吉业¹ 孙晓庆¹ 王相村¹ 卢波¹ 赵娟娟²

¹蒙阴县人民医院临床药学科，临沂　276200；²蒙阴县人民医院心内科，临沂　276200

收稿日期:2022-11-14 出版日期:2023-04-01 发布日期:2023-04-28
通讯作者: 陈吉业，Email：myxyyyjk@163.com
基金资助:
山东省药学会医院药学专项科研学术活动项目（yyyx2021 qn-14）；山东省学校卫生协会2022年度科研课题（SDWS2022039）

Detection of ABCB1, PON1, and CYP2C19 genotypes in patients with coronary heart disease and their clinical significance of guiding precise drug use after PCI

Chen Jiye¹, Sun Xiaoqing¹, Wang Xiangcun¹, Lu Bo¹, Zhao Juanjuan²

¹Department of Clinical Pharmacy, Mengyin County People's Hospital, Linyi 276200, China; ²Department of Cardiology, Mengyin County People's Hospital, Linyi 276200, China

Received:2022-11-14 Online:2023-04-01 Published:2023-04-28
Contact: Chen Jiye, Email: myxyyyjk@163.com
Supported by:
Hospital Pharmaceutical Special Scientific Research Academic Activity Project of Shandong Pharmaceutical Association (yyyx2021 qn-14); 2022 Scientific Research Project of Shandong School Health Association (SDWS2022039)

摘要/Abstract

摘要：

目的　探究蒙阴地区冠心病患者ABCB1、PON1、CYP2C19基因型分布特点及指导经皮冠状动脉介入（PCI）术后精准用药的临床意义。方法　本文为临床试验性研究，选取2019年5月至2021年10月在蒙阴县人民医院诊治的785例冠心病患者，均行基因型检测，对基因型的分布特征进行统计分析。依据基因型结果对需要行PCI术的患者分为正常代谢型组（183例）和慢代谢型组（115例）。正常代谢型组男129例、女54例，年龄63.0（53.3，70.0）岁，术后服用氯吡格雷75 mg/d；慢代谢型组男88例、女27例，年龄64.0（54.0，70.0）岁，术后服用替格瑞洛90 mg/次、2次/d或西洛他唑100 mg/次、2次/d，以上两组均联合服用阿司匹林100 mg/d，根据病情选择服用其他药物。于术后12个月内随访和比较两组主要心血管不良事件发生情况。采用秩和检验、χ²检验。结果　入选患者中ABCB1基因突变频率为61.14%（480/785）；PON1基因突变频率为67.64%（531/785）；CYP2C19快代谢基因型占40.89%（321/785），超快代谢基因型占0.89%（7/785），中间代谢基因型占43.82%（344/785），慢代谢基因型占14.39%（113/785）。本地区冠心病患者的氯吡格雷吸收与代谢相关基因突变频率较高。慢代谢型组患者精准用药后与正常代谢型组不良事件发生率比较，差异无统计学意义［13.91%（16/115）比9.84%（18/183）］（P>0.05）。结论　蒙阴地区冠心病患者氯吡格雷吸收与代谢相关基因突变率较高，依据基因型指导PCI术后精准用药具有重要临床意义。

关键词:

冠心病, 基因型, ABCB1, PON1, CYP2C19, 精准用药

Abstract:

Objective　To explore the distribution characteristics of ABCB1, PON1, and CYP2C19 genotypes in patients with coronary heart disease in Mengyin area and their clinical significance of guiding precise drug use after percutaneous coronary intervention (PCI). Methods　It was a clinical trial. A total of 785 patients with coronary heart disease who were diagnosed and treated in Mengyin County People's Hospital from May 2019 to October 2021 were selected consecutively. The genotype detection was performed for all the patients, and the distribution characteristics of genotype were statistically analyzed. The patients requiring PCI were divided into a normal metabolism group (183 cases) and a slow metabolism group (115 cases) according to the genotype detection results. In the normal metabolism group, 129 males and 54 females, aged 63.0 (53.3, 70.0) years, took clopidogrel 75 mg/d after surgery. In the slow metabolism group, 88 males and 27 females, aged 64.0 (54.0, 70.0) years, took ticagrelor 90 mg/time, twice a day or cilostazol 100 mg/time, twice a day. The two groups both took aspirin 100 mg/d, and other drugs were selected according to the conditions. The main adverse cardiovascular events were followed up within 12 months after operation and were compared between the two groups. Rank sum test and χ² test were used. Results　In the patients, the mutation frequency of ABCB1 gene was 61.14% (480/785); the mutation frequency of PON1 gene was 67.64% (531/785); CYP2C19 fast metabolism genotype accounted for 40.89% (321/785), ultra-fast metabolism genotype accounted for 0.89% (7/785), intermediate metabolism genotype accounted for 43.82% (344/785), and slow metabolism genotype accounted for 14.39% (113/785). The frequency of clopidogrel absorption and metabolism-related gene mutation was higher in patients with coronary heart disease in this region. There was no statistically significant difference in the incidence of adverse events between the patients in the slow metabolism group after precision medication and the normal metabolism group [13.91% (16/115) vs. 9.84% (18/183)] (P>0.05). Conclusion　The mutation rate of clopidogrel absorption and metabolism-related genes is high in patients with coronary heart disease in Mengyin area, and it is of important clinical significance to accurately use drugs after PCI according to the genotypes.

Key words:

Coronary heart disease, Genotype, ABCB1, PON1, CYP2C19, Precise medication

陈吉业孙晓庆王相村卢波赵娟娟.

冠心病患者ABCB1、PON1、CYP2C19基因型检测及指导PCI术后精准用药的临床意义 [J]. 国际医药卫生导报, 2023, 29(7): 957-961.

Chen Jiye, Sun Xiaoqing, Wang Xiangcun, Lu Bo, Zhao Juanjuan.

Detection of ABCB1, PON1, and CYP2C19 genotypes in patients with coronary heart disease and their clinical significance of guiding precise drug use after PCI [J]. International Medicine and Health Guidance News, 2023, 29(7): 957-961.

参考文献

[1] 马丽媛,王增武,樊静,等. «中国心血管健康与疾病报告2021»要点解读[J]. 中国全科医学,2022,25(27):3331-3346.DOI:10.12114/j.issn.1007-9572.2022.0506.
[2] 邱广泉,孔祥勇,马礼坤. CYP2C19、PEAR1和PON1基因多态性与抗血小板聚集功能及预后的关系[J]. 中国医院药学杂志,2022,42(13):1352-1356.DOI:10.13286/j.1001- 5213.2022.13.11.
[3] Yuan XW, Yuan SY, Wu GX, et al. Genetic polymorphism of clopidogrel metabolism related gene CYP2C19 gene in Chinese from Foshan area of Guangdong Province[J]. Hematology,2022,27(1):1056-1061.DOI:10.1080/16078454.2022.2121899.
[4] 张宪芬,张殿宝,韩婉青,等. CYP2C19基因指导非体外循环冠脉旁路移植术后抗血小板治疗的意义[J]. 国际医药卫生导报,2022,28(4):459-463.DOI:10.3760/cma.j.issn.1007- 1245.2022.04.004.
[5] 牛怀明,郭李平,邵新. 冠心病合并高血压患者CYP2C19基因多态性及不同基因型与氯吡格雷抵抗的关系[J]. 中国实用医刊,2020,47(7):26-29.DOI:10.3760/cma.j.cn115689- 20191108-07886.
[6] Palla M, Briasoulis A, Kondur A. Oral anticoagulants with dual antiplatelet therapy versus clopidogrel in patients after percutaneous coronary intervention: a meta-analysis[J].Am J Ther,2019,26(1):e143-e150.DOI:10.1097/MJT.0000000000000466.
[7] 郭玉梅,张琳,李海洲,等. 冠状动脉性心脏病合并高血压患者CYP2C19基因多态性及不同基因型与氯吡格雷抵抗的关系研究[J]. 中国实用医刊,2019,46(23):14-17.DOI:10.3760/cma.j.issn.1674-4756.2019.23.004.
[8] 王斌,刘爱云. 基因多态性影响药物敏感性在2型糖尿病用药中的应用效果及与血糖波动的相关性研究[J]. 国际医药卫生导报,2020,26(19):2884-2886.DOI:10.3760/cma.j.issn.1007-1245.2020.19.016.
[9] 后世翔,方存明,栾家杰,等. CYP2C19、ABCB1和PON1基因多态性对ACS病人PCI术后氯吡格雷治疗的影响[J]. 蚌埠医学院学报,2021,46(5):606-610.DOI:10.13898/j.cnki.issn.1000-2200.2021.05.012.
[10] Pilling LC, Türkmen D, Fullalove H, et al. Analysis of CYP2C19 genetic variants with ischaemic events in UK patients prescribed clopidogrel in primary care: a retrospective cohort study[J].BMJ Open,2021,11(12):e053905.DOI:10.1136/bmjopen-2021-053905.
[11] 袁双丽,袁圆,安晓婕,等.新疆地区冠心病患者氯吡格雷吸收与代谢相关基因CYP2C19、ABCB1、PON1的多态性分布研究[J].中国药房,2021,32(19):2388-2393.DOI:10.6039/j.issn.1001-0408.2021.19.14.
[12] 姚仲伟,李美锦,林虹,等. 宏基因组测序技术在不同年龄段儿童重症肺炎病原检测中的应用[J]. 国际医药卫生导报,2021,27(7):1023-1026.DOI:10.3760/cma.j.issn.1007- 1245.2021.07.019.
[13] Qian W, Chen L, Zhang L, et al. Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying CYP2C19 loss of function allele[J]. J Thorac Dis,2022,14(7):2591-2601.DOI:10.21037/jtd-22-740.
[14] 葛高顺,倪二茹,王莹莹,等. CYP2C19、PON1基因多态性与氯吡格雷在ACS行PCI术后血小板抑制功能的关联分析[J]. 国际检验医学杂志,2018,39(19):2386-2390.DOI:10.3969/j.issn.1673-4130.2018.19.014.
[15] 岳彩娟,王婧婧. 双联抗血小板治疗对不同CYP2C19基因型冠心病PCI术后伴血脂异常患者抗血小板效果研究[J]. 检验医学与临床,2022,19(3):354-356,360.DOI:10.3969/j.issn.1672-9455.2022.03.017.
[16] 董婧,石国华,黄澍,等. CYP2C19、ABCB1和PON1基因多态性与氯吡格雷抑制血小板聚集作用的相关性研究[J]. 中国医院药学杂志,2018,38(23):2464-2468.DOI:10.13286/j.cnki.chinhosppharmacyj.2018.23.17.
[17] Uzokov J, Alyavi B, Abdullaev A, et al. Antiplatelet therapy with clopidogrel taking into account CYP2C19 genetic polymorphisms in patients with coronary heart disease after coronary artery stenting[J]. Atherosclerosis,2021,331:e265-e265. DOI:10.1016/J.ATHEROSCLEROSIS. 2021.06.811.
[18] Naushad SM, Vattam KK, Devi YKD, et al. Mechanistic insights into the CYP2C19 genetic variants prevalent in the Indian population[J]. Gene,2021,784:145592.DOI:10.1016/j.gene.2021.145592.
[19] 奚炜,贾亮亮,金桂兰,等. 宜昌地区人群CYP2C19和PON1基因型分布与氯吡格雷抵抗风险相关性研究[J]. 中南药学,2021,19(6):1139-1143.DOI:10.7539/j.issn.1672- 2981.2021.06.021.
[20] Zhang Z, Bao Y, Cai L, et al. Cost-utility analysis of CYP2C19 genotype detection for selection of acid-suppressive therapy with lansoprazole or vonoprazan for patients with reflux esophagitis in China[J].Clin Drug Investig,2022,42(10):839-851.DOI:10.1007/s40261-022-01188-w.

冠心病患者ABCB1、PON1、CYP2C19基因型检测及指导PCI术后精准用药的临床意义

Detection of ABCB1, PON1, and CYP2C19 genotypes in patients with coronary heart disease and their clinical significance of guiding precise drug use after PCI

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

[1]	莫琳勤李杏张展苏严琳孙艳彬. 以格林模式为框架的强化护理模式在冠心病不稳定型心绞痛患者中的实践研究 [J]. 国际医药卫生导报, 2023, 29(8): 1160-1166.
[2]	戴海蓉凌宏忠曹光玲欧树玉谢继璜周晖. 非生殖器皮肤疣的HPV分型与临床特征分析 [J]. 国际医药卫生导报, 2023, 29(2): 236-.